Comment
Author: Admin | 2025-04-28
A Category 3 drug in Mexico.[citation needed]New Zealand: Ketamine is a Class C drug in New Zealand.[citation needed]Norway: Ketamine is a Class A drug in Norway.[citation needed]Singapore: Ketamine is a Class A drug in Singapore.[citation needed]Slovakia: Ketamine is a Schedule II drug in Slovakia.[citation needed]South Korea: Ketamine is illegal to possess and sell in South Korea.[citation needed]Spain: Ketamine is a Schedule IV drug in Spain.[70]Sweden: Ketamine is a Schedule IV drug in Sweden.[citation needed]Switzerland: Ketamine is a controlled substance specifically named under Verzeichnis B, when possessed or handled without a license. Medicinal use is permitted.[71]Taiwan: Ketamine is a Schedule III drug in Taiwan.[citation needed]Turkey: Ketamine is a 'green prescription' only substance[72] and illegal when sold or possessed without a prescription.[citation needed]United Kingdom: Ketamine is a Class B drug in the United Kingdom.[73]United States: Ketamine is a Schedule III drug in the United States.[citation needed]Poland: Ketamine is illegal to possess, manufacture and sell except for medical purposes. [74]Italy: Ketamine is a Schedule I drug in Italy. [75]See alsoResponsible useHallucinogensDissociativesArylcyclohexylaminesMXEPCPExternal linksKetamine (Wikipedia)Ketamine (Erowid Vault)Ketamine (Isomer Design)Ketamine (DrugBank)Esketamine (DrugBank)Ketamine (Drugs.com)Esketamine (Drugs.com)Ketamine (Drugs-Forum)MediaInterview with a Ketamine Chemist (VICE)The Experimental Ketamine Cure for Depression (VICE)Ketamine: Dreams and Realities (Jansen 2000, 2004)LiteratureDurieux, M., & Kohrs, R.T. (1998). Ketamine: teaching an old drug new tricks. Anesthesia and A nalgesia, 87 5, 1186-93. PMID: 9806706Mion, G. (2017). History of anaesthesia: The ketamine story–past, present and future. European Journal of Anaesthesiology (EJA), 34(9), 571-575. https://doi.org/10.1097/EJA.0000000000000638Krystal, J. H., Karper, L. P., Seibyl, J. P., Freeman, G. K., Delaney, R., Bremner, J. D., . . . Charney, D. S. (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Archives of General Psychiatry, 51(3), 199-214. http://dx.doi.org/10.1001/archpsyc.1994.03950030035004Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620References↑ Hall, D., Robinson, A. (September 2014). "INTRANASAL KETAMINE FOR PROCEDURAL SEDATION". Emergency Medicine Journal. 31 (9): 789.2–790. doi:10.1136/emermed-2014-204221.28. ISSN 1472-0205.↑ Clements, J.A.; Nimmo, W.S.; Grant, I.S. (1982). "Bioavailability, Pharmacokinetics, and Analgesic Activity of Ketamine in Humans". Journal of Pharmaceutical Sciences. 71 (5):
Add Comment